Medicare Prescription Drug Plans 2027: What the Formulary Shifts Mean for Your Wallet

The most significant shift for Medicare beneficiaries in 2027 is not a single premium hike, but a fundamental restructuring of how prescription drugs are priced and covered. While the standard Part B premium is projected to rise modestly, the real financial impact lies in the interplay between new negotiated drug prices and a record high out-of-pocket deductible. This creates a complex landscape where some medications become dramatically cheaper, yet the baseline cost to access coverage increases for everyone.

Understanding Medicare prescription drug plans 2027 requires looking past the monthly premium sticker. The Inflation Reduction Act has introduced a second round of negotiated prices for brand-name drugs, which directly lowers the cost of specific high-demand medications like Ozempic and Wegovy. However, this savings is offset by a Part D deductible that is jumping to its highest level ever. This divergence means that your personal savings or losses depend entirely on your specific formulary, your pharmacy network, and where you fall within the coverage phases.

The open enrollment period for these changes runs from October 15 through December 7, 2026. This is the critical window to assess whether your current plan aligns with the new 2027 rules. Many retirees assume that keeping their existing plan is the safest bet, but the annual adjustments to formularies and cost-sharing structures can significantly alter the value of that decision. A detailed analysis of these prescription details is essential for anyone managing chronic conditions or taking multiple medications.

The Negotiated Price Revolution

Starting January 1, 2027, Medicare’s second round of negotiated drug prices takes effect for 15 additional brand-name drugs. This brings the total number of Medicare-negotiated drugs to 25, a major expansion from the initial ten that launched in 2026. The most high-profile change involves the GLP-1 class of medications used for diabetes and weight management. Specifically, the price Medicare pays for a month’s supply of Ozempic, Rybelsus, and Wegovy drops from $959 to $274, representing a 71% cut. This is not a voluntary discount but a federal requirement that sets a ceiling price for these treatments.

The impact extends beyond diabetes care. Xtandi, a medication used for prostate cancer, sees a 48% reduction, falling from $13,480 to $7,004. The other 13 drugs on the list treat conditions ranging from asthma and COPD to multiple myeloma and bipolar disorder, with discounts mostly between 40% and 85% off their 2024 list prices. Medicare projects that across all 15 newly negotiated drugs, the program will save $12 billion, a 44% cut from what it spent on these same drugs in 2024. While this is a programmatic savings figure, it signals a substantial shift in the baseline cost of these therapies.

For the individual beneficiary, this means the negotiated price becomes the maximum amount the plan can charge for these specific drugs. Plans and pharmacies are required to make these prices available to everyone who qualifies. This is a tangible benefit that directly lowers the cost of some of the most expensive and sought-after medications in the market. It is a clear win for patients who rely on these drugs, as the previous market pricing was often prohibitive for fixed-income retirees. The key is that these savings are locked into the system, not subject to annual plan-by-plan negotiation.

The Deductible Hike and Premium Subsidy End

While drug prices are falling, the barrier to entry for coverage is rising. The Part D deductible is jumping from $615 to $700 in 2027, the largest increase in the program’s history. This means that before your plan begins to cover the full cost of any prescription, you must pay this amount out of pocket. For beneficiaries who are just starting a new medication or have had a gap in coverage, this higher threshold can be a significant financial hurdle, even if the drugs they eventually take are covered at lower negotiated rates.

Simultaneously, the federal subsidy that has been propping up standalone Part D drug plans is expiring. For the past two years, the Part D Premium Stabilization Demonstration has cut stand-alone drug-plan premiums by an average of $16 a month. This subsidy disappears after 2026. CMS states that insurers have had enough time operating under the redesigned drug benefit that they no longer need the support. However, this does not mean premiums are spiking across the board. The average premium for stand-alone Medicare Part D prescription drug plans is expected to increase by less than $1 a month, a modest adjustment compared to the larger hikes seen in other parts of Medicare.

Formulary and Tier Risks

One of the easiest changes to overlook involves where your prescription appears on your plan’s drug formulary. Medicare Part D plans organize covered medications into tiers, with different copayments or coinsurance amounts depending on the drug and plan. A medication that previously required a $10 copayment could become more expensive if its tier or cost-sharing terms change for 2027. Even if the drug itself is not subject to price negotiation, its position on the formulary can shift, moving it to a higher tier with a larger share of the cost borne by the patient.

Beneficiaries must compare the 2026 and 2027 formularies for every prescription they take, including medications they use only occasionally. Plans can adjust their covered medications, pharmacy networks, and cost-sharing requirements from one year to the next. A plan that worked well in 2026 could become considerably more expensive in 2027, even if your medications haven’t changed. This is why a detailed review of the formulary is crucial, as it determines the actual out-of-pocket cost you will face at the pharmacy counter.

The Medicare Plan Compare tool allows beneficiaries to enter their medications and compare estimated costs at different pharmacies. For someone taking several maintenance medications, even relatively small differences in monthly copayments can add up to meaningful expenses over a year. When reviewing 2027 Medicare prescription coverage, check whether your pharmacy remains in-network, whether it has preferred status, and whether mail-order options could reduce costs. The assumption that your neighborhood pharmacy will remain the most affordable option is no longer guaranteed, as preferred pharmacy networks and their arrangements can change annually.

Coverage Restrictions and New Scrutiny

In addition to tier changes, beneficiaries may face new coverage restrictions. Some retirees could encounter narrower formularies or new requirements for prior authorizations for certain medications. As insurers continue adjusting to major Inflation Reduction Act reforms, 2027 may bring more changes than usual. For people whose retirement savings are stretched thin, even a small change in prescription coverage can impact their budget. It is not just about the price of the drug, but also the ease with which you can access it.

The 2026 survey by eHealth found that 42% of Medicare beneficiaries named at least one thing they were dissatisfied with in their coverage, with high premiums and out-of-pocket costs leading the list. About a third of Medicare beneficiaries told eHealth their out-of-pocket costs are running higher than expected. This dissatisfaction is likely to persist into 2027, especially for those whose plans introduce new restrictions or move their drugs to less favorable tiers. The complexity of the new system means that passive renewal is no longer the safest strategy for managing prescription costs.

Strategic Actions for 2027

To navigate these changes, beneficiaries should start by listing all their current medications and checking their status in the 2027 formulary of their current plan. Use the Medicare Plan Compare tool to see how their costs would look under alternative plans, paying close attention to the deductible and tier structures. The end of the premium subsidy means that standalone plans may see slight increases, while Medicare Advantage premiums are projected to fall from $14.37 in 2026 to $12 in 2027. This shift in the premium landscape could make MA plans more attractive for some, but only if their formularies and networks align with your needs.

The official 2027 Part B premium, projected at $209.50, will be announced by CMS in late November, with mailed notices expected in December. While this is a smaller rise than the 9.7% increase seen in 2026, it still represents a significant cost for those on fixed incomes. The best strategy is to act before the enrollment period closes on December 7. By carefully reviewing your formulary, understanding the new negotiated prices, and comparing your options, you can ensure that your 2027 coverage is both affordable and comprehensive. The details matter, and the time to check them is now.